Semantic Definition Differences Not Inconsistent With Claim Construction
Client Alert | 1 min read | 01.30.08
In Innogenetics, N.V. v Abbott Laboratories (Nos. 2007-1145, -1161, January 17, 2008) the Federal Circuit reverses a district court’s JMOL that a claim was not anticipated, and remands for a new trial. The patent technology at issue relates to diagnostic tools for detecting and classifying hepatitis C types using specific short strands of nucleic acids, “probes”, that bind to target DNA. Innogenetics sued Abbott for patent infringement. At trial, Abbott’s expert testified that the Resnick patent anticipated claim 1 of Innogenetics’ patent, and specifically that the Resnick patent disclosed probes that “distinguish” between two hepatitis C types. The word “distinguish” was objected to by Innogenetics as inappropriate, arguing that Abbott’s expert report defined “a method of genotyping” as the process of “detecting and classifying.”
The district court construed “method of genotyping,” to mean a method that “distinguishes” among types. Before the case went to the jury, the district court granted JMOL of no anticipation based on its determination that Abbott’s expert testimony “rested on an inaccurate understanding of the construction of the limitation genotyping.” Abbott’s motion for a new trial was denied.
Using an abuse of discretion review standard, the Federal Circuit finds that the district court’s determination that the expert’s testimony was tainted by an inaccurate understanding of the term genotyping is clearly erroneous. Despite the semantical difference, the panel discerns no difference in the meaning between the definitions used by the expert and the one adopted by the district court, and finds that the expert’s failure to use the district court’s exact word does not change the substance of his testimony or render it inapplicable.
Insights
Client Alert | 6 min read | 10.26.26
Executive Order Creates Women’s Health Task Force, Rescinds Prior Initiatives
On October 19, 2026, President Trump signed an executive order (EO) titled “Advancing Women’s Health to Improve Outcomes in All Phases of Life,” establishing new federal infrastructure dedicated to improving women’s health research, clinical translation, and coordinated policy leadership. The EO creates a White House Women’s Health Task Force and directs the U.S. Department of Health and Human Services (HHS) to establish a new Women’s Health Division within the National Institutes of Health (NIH).
Client Alert | 7 min read | 10.22.26
Africa, MENA, and the Arbitration Act 2025: LCIA’s Latest Report
Client Alert | 4 min read | 10.22.26
CMS Proposal Would Require Extensive Provider Directory Changes in MA
